FIB-4 value before DAA therapy as a predictor of Esophageal varices progression after SVR12 with DAA therapy
DOI:
https://doi.org/10.59058/jaimc.v21i3.27Keywords:
Hepatitis C, EV, Esophageal varices, Direct acting antivirals, Sustained viral response, FIB-4Abstract
Objective: The goals of this study were to better understand the impact that direct-acting antivirals (DAAs) have on portal hypertension once a sustained viral response (SVR) has been achieved. Therefore, it is important to look at economical and noninvasive predictors. We looked into the factors that contributed to the emergence of EVs in hepatitis C infected patients after SVR with DAAs.
Study Design: Open-Label Single-Arm clinical trial
Setting: Department of Gastroenterology, AIMC/ Jinnah Hospital, Lahore
Duration of Study: The duration of study was 3 years and 4 months ( from June 2017 to October 2020)
Methods: 109 patients who attained SVR post DAA therapy were enrolled in this study and their pre- and post-treatment esophagogastroduodenoscopy (EGD) findings were compared. EV progression and non-progression were assessed. Additionally, EV cumulative advancement rates were examined.
Results: Before DAA treatment, the fibrosis-4 index (FIB-4) was the only substantial predictor of EVs progression after SVR ( 95% confidence intervals: 1.25-1.54, odds ratios: 1.45, p = 0.02). Based on ROC curve analysis, patients with a FIB-4 of 8.5 or higher had a higher risk of EVs (sensitivity = 0.69, specificity = 0.91, positive predictive value = 0.36, negative predictive value = 0.98).
Conclusion: EV development is possible in patients with FIB-4≥ 8.5, so EGD surveillance should continue after SVR.
Keywords:
Hepatitis C, EV, Esophageal varices, Direct acting antivirals, Sustained viral response, FIB-4
References
REFERENCES
Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroen- terol 2018; 53: 557–65.
Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of gle- caprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2018; 67: 505–13.
Curry MP, O’leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618–28.
Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology 2017; 66: 1083–9.
Maruyama H, Kobayashi K, Kiyono S, et al. Incidence and hemo- dynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. Int J Med Sci 2019; 16: 1614–20.
Afdhal N, Everson GT, Calleja JL, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 2017; 24: 823–31.
Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroen- terology 2017; 153: 1273–83.e1.
Grgurevic I, Bozin T, Madir A. Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards? Clin Exp Hepatol 2017; 4: 181–6.
D’ambrosio R, Aghemo A, Rumi MG, et al. The course of esophageal varices in patients with hepatitis C cirrhosis respond- ing to interferon/ribavirin therapy. Antiviral Ther 2011; 16: 677–84.
De Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743–52.
Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 2017; 66: 1980–8.
The Japan Society for Portal Hypertension. The General Rules for Study of Portal Hypertension. 3rd edn. Tokyo: Kanehara, 2013.
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–6.
Kanda Y. Investigation of the freely available easy-to-use soft- ware ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8.
Yuri Y, Nishikawa H, Enomoto H, et al. Impact of sustained virolog- ical response for gastroesophageal varices in hepatitis-C-virus- related liver cirrhosis. J Clin Med 2019; 9: 95.
Puigvehí M, Londoño M-C, Torras X, et al. Impact of sustained virological response with DAAs on gastroesophageal varices and
Baveno criteria in HCV-cirrhotic patients. J Gastroenterol 2020;
: 205–16.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD, Practice Guide- lines Committee of American Association for Study of Liver Diseases, Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroe- sophageal varices and variceal hemorrhaging in cirrhosis. Am J Gastroenterol 2007; 102: 2086–102.
Kraja B, Mone I, Akshija I, Koçollari A, Prifti S, Burazeri G. Predictors of esophageal varices and first variceal bleeding in liver cirrhosis patients. World J Gastroenterol 2017; 23: 4806– 14.
Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch
J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. J Hepa- tol 2010; 53: 273–82.
Ishikawa T, Sasaki R, Nishimura T, et al. A novel therapeutic strat- egy for esophageal varices using endoscopic treatment com- bined with splenic artery embolization according to the Child- Pugh classification. PLoS One 2019; 14: e0223153.
Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016; 65: 692–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Attique Abou Bakr, Amtiaz Ahmad, Tayyab Shazad, Madeha Akram, Fawad Iqbal Janjua
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
